Targeting angiogenesis in advanced cervical cancer
Hybrid Shorts Patients with advanced stage or recurrent cervical cancer represent a population with limited chemotherapeutic options.More specifically, patients with recurrent disease have a poor salvage rate, with a 5-year survival rate of less than 10%.This year, the first prospective phase III clinical trial exploring the anti-angiogenic agent,